OncoArendi plans IPO for March/April

Biotechnological firm OncoArendi Therapeutics, which specializes in oncological pharmaceuticals, plans to offer 500k-2 million new shares under its IPO planned for the turn of March and April, the company said. “The company's intention is to offer some 90 percent of shares to institutional investors and 10 percent to individual investors,” OncoArendi said. The company's significant shareholders agreed to a lock-up period of 360 days. The date and schedule of the IPO will depend on securing the approval of its prospectus by the Financial Supervision Authority KNF.